Immetas Therapeutics

Immetas Therapeutics discovers and develops new therapies that modulate the innate immune system to treat age-related cancers and inflammatory diseases. The company’s approach is based on emerging evidence that chronic, low-grade inflammation is a fundamental process controlling aging and age-related diseases, supported by clinical evidence to mitigate developmental risks. Immetas was founded by J. Gene Wang, M.D. (a veteran in immunology/inflammation and oncology discovery and translational drug development) and David Sinclair, Ph.D. (a professor of genetics at Harvard Medical School and a leader in the molecular mechanisms of aging). The lead program in the company’s growing pipeline focuses on engineered bispecific antibodies to modulate inflammation within the tumor microenvironment and overcome resistance to conventional immune checkpoint therapies.